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REVIEW
Abstract: Stress urinary incontinence (SUI) is the most common form of urinary incontinence
and occurs more frequently in women than in men. Duloxetine is a balanced dual serotonin
(5-HT) and norepinephrine (NE) reuptake inhibitor and shows no relevant binding affinity for
histaminergic, dopaminergic, cholinergic, and adrenergic receptors. The efficacy of duloxetine
in SUI is based on the inhibition of the presynaptic reuptake of 5-HT and NE in Onuf’s
nucleus of the sacral spinal cord, whereby it may increase the concentration of 5-HT and NE
in the synaptic cleft. The effectiveness of duloxetine was studied in a cat model of acetic acid-
induced bladder irritation. The results showed that in cats with previous irritated bladder
function, there was a dosage-dependent improvement of bladder capacity and periurethral
electromyography (EMG) activity. In women with SUI, it is assumed that the clinical efficacy
of duloxetine is based on stronger urethral contraction and persistent sphincter tone during
the storage phase. In clinical trials in women with SUI, duloxetine has demonstrated efficacy
in reducing incontinence episodes and increasing quality of life. Nausea was the most common
adverse event and the main cause for discontinuation. In summary, duloxetine appears to be a
promising new option for the treatment of SUI.
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Introduction
Urinary incontinence is defined by the International Continence Society as an
involuntary passage of urine and is commonly found in elderly people. With a rate of
approximately 50% prevalence, stress urinary incontinence (SUI) is the most common
form of urinary incontinence, and is more frequently found in women than in men
(Hampel et al 1997) because of the vulnerability of the female sphincter mechanism.
Initial treatment for SUI should include lifestyle intervention and supervised pelvic
floor muscle training. The International Consultation on Incontinence (ICI) actually
recommends that conservative treatment may be augmented with appropriate drug
therapy and mentions dual serotonin (5-HT) and norepinephrine (NE) reuptake
inhibitors as examples of therapy for SUI.
Duloxetine is the first medication developed for SUI and has been also developed
for the treatment of depression and pain caused by diabetic peripheral neuropathy
(Figure 1). This review focuses on duloxetine in the treatment of SUI. The action of
duloxetine is associated with the reuptake inhibition of 5-HT and NE at the presynaptic
neuron in Onuf’s nucleus (the pudendal nerve motor nucleus) of the sacral spinal
cord (Michel and Peters 2004).
Onuf’s nucleus
The Onuf’s nucleus is a distinctly confined neuronal group in the ventral horn of
the sacral spinal cord, which extends in humans over 2 segments from S1 to S2
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or S2 to S3. Onufrowicz originally discovered it as
nucleus X (Onufrowicz 1889; 1890).
In experimental animal studies conducted with cats,
dogs, rabbits, and subhuman primates (retrograde labeling
by injection of horseradish peroxidase [HRP]), the Onuf’s
nucleus was identified as the origin of the innervation of
the external sphincter of the urethra and the anus. Generally,
the Onuf’s nucleus contains 300–500 neurons on each side
in animals; however, humans have an average of 625 neurons
(Durant et al 1988; Downie et al 1991; Hosoya et al 1991;
Jost 1997).
The corresponding neurons for the bladder sphincter
were discovered in the ventromedial (cats) or ventrolateral
(rhesus monkey) part, and for the anal sphincter, in the
dorsolateral (cats) and dorsomedial (rhesus monkey) part
of the nucleus.
Neurotransmitters
The motoneurons in the Onuf’s nucleus are densely packed
with different neurotransmitters (eg, NE, 5-HT, and
dopamine) and receptors. The motoneurons in the Onuf’s
nucleus, which are involved in bladder–sphincter function,
are surrounded by a dense accumulation of norepinephric
and serotonergic nerve terminals, which primarily carry
5-hydroxytryptamine2 (5-HT2) and alpha-1 receptors (Thor
2003).
Stimulation of these receptors leads to a marked increase
in the tonus of the guarding reflex, which prevents voiding
by a sudden increase in abdominal pressure initiated by eg,
coughing and sneezing. An effect of the neurotransmitters
5-HT and NE, on the motoneuron was only detected in the
presence of glutamate. As a result, a glutamate-induced and
a 5-HT- and NE-supported activation of the sphincter
motoneurons does not appear to impair the bladder–
sphincter synergy (Thor 2003).
Pharmacological properties of
duloxetine
Duloxetine is a balanced 5-HT and NE reuptake inhibitor.
There is a weak inhibition of dopamine and no significant
affinity for histaminergic, dopaminergic, cholinergic, and
adrenergic receptors (Table 1) (Wong et al 1993).
The efficacy of duloxetine in SUI is based on the
inhibition of the presynaptic reuptake of 5-HT and NE in
the Onuf’s nucleus of the sacral spinal cord, whereby it may
lead to an increased concentration of 5-HT and NE in the
synaptic cleft (Michel and Peters 2004).
The effects of duloxetine on the lower urinary tract were
investigated in animal experiments. Duloxetine showed a
significant increase of bladder capacity and sphincter–
electromyography (EMG) activity. Cats, whose bladders
were initially pretreated with acetic acid, showed a dose-
dependent improvement of the bladder capacity (5-fold) and
periurethral EMG activity (8-fold) of the striated sphincter
musculator only during the storage phase of the micturition
cycle (Karl and Katofiase 1995).
In women with SUI, it is assumed that an increased
urethral contraction and a sustained sphincter tonus during
the filling phase may explain the clinical efficacy of
duloxetine treatment. The pharmacokinetics of duloxetine
have been examined in healthy adults and in patients with
SUI or mixed urinary incontinence (Table 2) (Ishigooka et
al 1997; Sharma et al 2000; Lantz et al 2003; Skinner et al
2004).
Duloxetine hydrochloride (C18 H19 NOS.HCL; MW333,
88) is a (+)-(S)-N-Methyl-3-(1-naphthyloxy-2-thienyl)-
propylamine Hydrochloride and is approximately 96%
bound to human plasma protein.
Duloxetine is extensively metabolized by oxidative
enzymes (cytochrome P1A2 [CYP1A2] and cytochrome
Figure 1 Duloxetine hydrochloride. Chemical name: (+)-(S)-N-Methyl-3-(1-
naphthyloxy-2-thienyl)-propylamine Hydrochloride, (C18 H19 NOS.HCL).
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P2D6 [CYP2D6]), followed by a conjugation. A large
intersubject variability (due to gender, age, smoking status,
and CYP2D6 metabolizer status) has been proven.
The average elimination half-life value after oral intake
of duloxetine is 12 hours. The recommended dose of
duloxetine for the treatment of SUI is 40 mg twice a day
regardless of mealtime. If a woman still experiences
troublesome events after 4 weeks, the dosage can be reduced
to 20 mg twice a day (Eli Lilly Nederland 2004).
Contraindications
Contraindications are pregnancy and lactation. Duloxetine
should not be used in combination with nonselective,
irreversible monoamine oxidase inhibitors. Duloxetine
should not be used in combination with CYP1A2 inhibitors
like fluvoxamine, ciprofloxacin, enoxacine, since the
combination results in elevated plasma concentration of
duloxetine. Further contraindications are liver disease
resulting in hepatic impairment and hypersensitivity to the
active substance or to any of the excipients (Eli Lilly
Nederland 2004).
Clinical results
The therapeutic efficacy of doses of 40 mg twice a day has
been demonstrated in 4 double-blind placebo-controlled
studies. Of the 1913 women between 22 and 83 years of
age who participated in these studies, 958 patients received
duloxetine and 955 received a placebo.
The goal of the studies was to examine the frequency of
incontinence episodes (IEF) obtained from diary notes and
the analysis of quality-of-life questionnaires (Incontinence
Quality of Life [I-QOL] and Patient Global Impression of
Improvement [PGI-I]) specially designed for urinary
incontinence. In all four studies, women treated with
duloxetine demonstrated a 50%–58% median decrease in
IEF compared to 27%–40% seen with placebo (Norton et
al 2002; Dmochowski et al 2003; Millard et al 2004; van
Kerrebroeck et al 2004).
Phase II study
The double-blind, randomized, placebo-controlled dose-
finding study of 553 women (aged between 18–65) with
SUI (Norton et al 2002) took place over a period of 12 weeks.
A total of 415 patients received duloxetine: 138 patients
received 20 mg/day; 137 patients received 40 mg/day; 140
patients received 80 mg/day. 138 patients received a placebo
(Norton et al 2002).
The study results showed a significant and clinically
relevant reduction in urinary incontinence episodes with
duloxetine. The last-visit analysis showed a significant but
not dose-dependent reduction in IEF. The pooled diary data
showed a dose-dependent pattern. While the I-QOL data
“paralleled” the dose-dependent response of the pooled IEF,
only the change at 80 mg/day were statistically significant.
Thus, 80 mg/day was then used for the subsequent Phase III
studies.
Clinical Phase III studies
Overall, 3 double-blind, randomized, placebo-controlled
Phase III studies have been conducted worldwide. In all
studies, the female patients were treated over a period of 12
weeks with 40 mg duloxetine twice daily compared with
placebo. Included in the study were female patients
predominantly with symptoms of SUI and who experienced
7 or more incontinence episodes a week (Dmochowski et al
2003; Millard et al 2004; van Kerrebroeck et al 2004). The
bladder capacity should have been ≥ 400 ml, and the cough
and stress-pad-test should have been positive. Female
patients who had predominantly symptoms of urge
incontinence were excluded from these studies. Female
patients who conducted stable pelvic floor muscle training
(PFMT) and patients who had prior incontinence surgery
were not excluded.
The efficacy was evaluated based on the reduction of
the IEF, which was collected with patient diaries and with
the aid of the I-QOL and PGI-I questionnaires that evaluated
quality of life. The I-QOL questionnaire collects data in
3 subcategories: avoidance and limiting behavior, psycho-
social impact, and social embarrassment. The PGI-I
questionnaire allows a self-evaluation based on improvement
of the clinical picture by the patient (Tables 3 and 4). Overall,
the data of the Phase III studies were comparable with those
of the Phase II study.
Table 2 Properties of duloxetine
Indication: SUI
Mechanism of action: Dual serotonin and norepinephrine
reuptake inhibition leading to increased
urethral sphincter activation
Dosage and administration: 40 mg oral twice daily
Pharmacokinetic profile: Cmax: 50 ng/mL, time to Cmax: 6 h,
elimination half-life: 12 h
Abbreviations: Cmax, maximum concentration; h, hours; SUI, stress urinary
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The 3 Phase III double-blind studies, conducted over a
period of 12 weeks, continued with an open phase during
which the efficacy was evaluated in 3-month intervals using
the PGI-I questionnaire. After 12 months of treatment, 82%
of patients viewed their condition as improved.
Study conducted in women with severe
SUI
One double-blind placebo-controlled study, in which
patients dose escalated from duloxetine 40 mg bid to 60 mg
bid, was conducted in women (n = 109 women, age from
33–75 years, with predominant symptoms of SUI), who were
suffering from severe SUI (more than 14 incontinence
episodes per week) and were awaiting surgery. The results
showed a significant reduction in the frequency of
incontinence episodes (–60% vs –27%, p < 0.001), a
significant improvement in the I-QOL score (10.6% vs 2.4%,
p = 0.003) and a reduction in pads (–34.5% vs. –4.8%,
p = 0.008) in the duloxetine group compared with placebo
(Cardozo et al 2004). Twenty percent (10/49) of patients
treated with duloxetine were no longer interested in surgery
following the 8-week treatment phase compared to no
(0/45) patients in the placebo group (p = 0.001).
Study comparing duloxetine alone with
PFMT and in combination
One study with active treatment comparison between
duloxetine and PFMT, alone and in combination, was
conducted. This placebo-controlled study included 201
women, aged 18–75 years, with predominant symptoms of
SUI. Both duloxetine alone and duloxetine in combination
with PFMT significantly (p < 0.05) reduced the median IEF
by 57%, compared with 35% reduction with PFMT alone
(29% reduction with no treatment) (Ghoniem et al 2005).
The mean total I-QOL score was increased by 13.1 with
combination therapy (p < 0.05 vs no treatment) compared
with increases of 8.3 for duloxetine alone, 7.8 for PFMT
alone, and 4.8 for no treatment. The median decreases in
pad use were: for the combination 46%, for duloxetine alone,
35%; for PFMT alone, 25% (all p < 0.05 vs no treatment);
and for no treatment, 10%.
Tolerability
Tolerability of duloxetine was evaluated based on the
occurrence of adverse events (AE), discontinuations because
of AE, vital parameters, electrocardiograms, and laboratory
tests. Adverse events were evaluated by the time of
occurrence, if they occurred for the first time, or if they
worsened in the course of treatment (Dmochowski et al
2003; Millard et al 2004; van Kerrebroeck et al 2004).
Nausea, dry mouth, fatigue, insomnia, constipation,
headache, dizziness, somnolence, and diarrhea were
reported signficantly more often under duloxetine treatment
compared with placebo and occurred at least in 5% of all
Table 3 Duloxetine in the treatment of SUI: Results of 3 Phase III efficacy studies, duloxetine 40 mg twice daily
IEF
median MTBV PGI-I
reduction improvement I-QOL improvement Author/study
Duloxetine 50% 20.0 min 11.1 62% Dmochowski et al 2003
Placebo 27.5% 1.7 min 6.8 39.6%
p<  0.001 < 0.001 < 0.001 < 0.001
Duloxetine 54% 20.4 min 10.3 74% Millard et al 2004
Placebo 40% 8.5 min 6.4 64%
p 0.05 < 0.001 0.007 0.03
Duloxetine 50% 15.0 min 5.5 56.2% van Kerrebroeck et al 2004
Placebo 29.3% 3.8 min 4.1 48.2%
p 0.002 < 0.001 0.13 ns
Abbreviations: IEF, incontinence episode frequency; I-QOL, Incontinence Quality of Life Questionnaire; MTBV, mean time between voids; min, minimum; ns, not
significant; PGI-I, Patient Global Impression-Improvement; SUI, stress urinary incontinence.
Table 4 Duloxetine in the treatment of SUI: patients with
IEF ≥ 14 per week
IEF median
decrease Author/Study
Duloxetine 58% Norton et al 2002
Placebo 30% Phase II
p 0.045
Duloxetine 55.9% van Kerrebroeck et al 2004
Placebo 26.8% Phase III
p<  0.001
Abbreviations: IEF, incontinence episode frequency; SUI, stress urinary
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female patients. Nausea was the most common adverse event
and was reported within the first few days after start of
treatment (in 64% within 2 days). The intensity of the
adverse events was mostly mild to moderate. Fifty-two
percent of patients with nausea reported resolution of the
symptoms by 1 week and 81% within 1 month. The
discontinuation rate due to AE was significantly higher in
the duloxetine group compared with the placebo group,
where nausea was reported as the most frequent reason for
discontinuation.
There were no clinically relevant effects on blood
pressure and heart frequency. The analysis of the corrected
QT interval showed no arrhythmogenic tendencies under
duloxetine (Dmochowski et al 2003).
Current status
Duloxetine is approved throughout the European Union for
the treatment of moderate to severe SUI in women. For a
long time, the rational treatment of SUI was in the domain
of surgical procedures. With the availability of duloxetine,
there is now a pharmacological treatment that has been
shown to be efficacious and tolerable, and as a result
broadens the spectrum of treatment for this indication.
Use in depression and pain
Due to its equivalent reuptake inhibition of 5HT2 and NE
and demonstrated low binding affinity for neurotransmitter
receptors, duloxetine seems to be superior as an anti-
depressant drug to reuptake inhibitors for just one
monoamine. Duloxetine is therefore also approved for the
treatment of depression. In comparative studies, duloxetine
was observed to be more effective than both fluoxetine and
paroxetine on several measures of depression (Goldstein et
al 2002, 2004). Duloxetine is different from fluoxetine
because of its dual nature of balanced serotonin and
noradrenalin reuptake inhibition. Serotonin and norepine-
phrine are thought to inhibit pain via descending pain
pathways (Goldstein et al 2005). In addition, duloxetine is
approved by the US Food and Drug Administration for the
treatment of diabetic peripheral neuropathic pain. Other
antidepressants such as venlafaxine, which also have dual
reuptake inhibition, lack the balance in reuptake inhibition
(Katofiasc et al 2002).
Conclusion
In the European Union, duloxetine is approved for the
treatment of women with moderate to severe forms of SUI
(women were investigated with predominant symptoms of
SUI in the discussed studies).
Duloxetine, alone and in combination with pelvic floor
training, significantly reduced (p < 0.05) in median
incontinence episode frequency (57% vs 35% pelvic floor
training alone; 29% no treatment). Combined treatment
(duloxetine and pelvic floor training) was superior with
regard to reduction in pads and improvement of quality of
life. Hence, combination with pelvic floor training (with
good compliance) may be appropriate. The recommended
dose is 40 mg twice daily.
Rational management of SUI has long been the domain
of surgical intervention. Duloxetine, for the first time,
appears to be a therapeutic approach with well documented
efficacy and tolerance, thus widening the spectrum of
treatment options for this indication.
References:
Cardozo L, Drutz HP, Baygani SK, et al. 2004. Pharmacological treatment
of women awaiting surgery for stress urinary incontinence. Am Coll
Obstet Gynecol, 104:511–19.
Dmochowski RR, Miklos JR, Norton PA, et al. 2003. Duloxetine versus
placebo for the treatment of North American women with stress urinary
incontinence. J Urol, 170:1259–63.
Downie J, Espey M, Gajewski J. 1991. Alpha 2-adrenoceptors not imidazole
receptors mediate depression of a sacral spinal reflex in the cat. Eur J
Pharmacol, 195:301–4.
Durant P, Lucas P, Yaksh T. 1988. Micturition in the unanesthetized rat:
spinal vs. peripheral pharmacology of the adrenergic system.
J Pharmacol Exp Ther, 245:426–35.
Eli Lilly Nederland BV. 2004. Yentreve: summary of product characteristics
[online]. Accessed 11 Oct 2004. URL: http://www.emea.eu.int/
humandocs/Humans/EPAR/yentrve/yentreve.htm.
Ghoniem GM, Van Leeuwn JS, Elser DM, et al. 2005. A randomized
controlled trial of duloxetine alone, pelvic floor muscle training alone,
combined treatment, and no active treatment in women with stress
urinary incontinence. J Urol, 173:1453–4.
Goldstein DJ, Lu Y, Detke MJ, et al. 2004. Duloxetine in the treatment of
depression: a double-blind placebo-controlled comparison with
paroxetine. J Clin Psychopharmacol, 24:389–99.
Goldstein DJ, Lu Y, Detke MJ, et al. 2005. Duloxetine vs placebo in patients
with painful diabetic neuropathy. Pain, 116:109–18.
Goldstein DJ, Mallinckrodt C, Lu Y, et al. 2002. Duloxetine in the treatment
of major depression disorder: a double-blind clinical trial. J Clin
Psychiatry, 63:225–31.
Hampel C, Wienhold D, Benken N, et al. 1997. Prevalence and natural
history of female incontinence. Eur Urol, 32(Suppl 2):3–12.
Hosoya Y, Okado N,Suiura Y, Kohno K. 1991. Coincidence of “ladder-
like patterns” in distributions of monoaminergic terminals and
sympathetic preganglionic neurons in the rat spinal cord. Exp Brain
Res, 86:224–8.
Ishigooka J, Nagata E, Takahashi A, et al. 1997. Simultaneous monitoring
of inhibition of serotonin uptake by platelets and plasma concentration
following administration of duloxetine, a new antidepressant candidate,
to healthy volunteers. Curr Ther Res, 58:679–92.
Jost WH (ed). 1997. Neurologie des Beckenbodens. London, Glasgow,
Weinheim: Chapman & Hall.Therapeutics and Clinical Risk Management 2005:1(4) 264
Jost and Marsalek
Karl KB, Katofiasc MA. 1995. Effects of duloxetine, a combined serotonin
and norepinephrine reuptake inhibitor, on central neural control of
lower urinary tract function in the chloralose-anesthetized female cat.
J Pharmacol Exp Ther, 274:1014–24.
Katofiasc MA, Nissen J, Audia JE, et al. 2002. Comparison of the effects
of serotonin selective, norepinephrine selective, and dual serotonin
and norepinephrine reuptake inhibitors on lower urinary tract function
in cats. Life Sci, 71:1227–36.
Lantz RJ, Gillespie TA, Rash TJ, et al. 2003. Metabolism, excretion, and
pharmacokinetics of duloxetine in healthy human subjects. Drug Metab
Dispos, 31:1142–50.
Michel MC, Peters SL. 2004. Role of serotonin and noradrenaline in stress
urinary incontinence. BJU Int, 94(Suppl I):23–30.
Millard RJ, Moore K, Rencken R, et al. 2004. Duloxetine vs placebo in
the treatment of stress urinary incontinence: a four-continent
randomized clinical trial. BJU Int, 93:311–18.
Norton P, Zinner N, Yalcin I, Bump R. 2002. Duloxetine versus placebo in
the treatment of stress urinary incontinence. Am J Obstet Gynecol,
187:40–8.
Onufrowicz B. 1889. Notes on the arrangement and function of the cell
groups of the sacral region of the spinal cord. J Nerv Men Dis, 26:498–
504.
Onufrowicz B. 1890. On the arrangement and function of the cell groups
of the sacral region of the sacral spinal cord in man. Arch Neurol
Psychopathol, 3:387–411.
Sharma A, Goldberg MJ, Cerimele BJ. 2000. Pharmacokinetics and safety
of duloxetine, a dual serotonin and norepinephrine reuptake inhibitor.
J Clin Pharmacol, 40:161–7.
Skinner MH, Kuan HY, Skerjanec A, et al. 2004. Effect of age on the
pharmacokinetics of duloxetine in women. Br J Clin Pharmacol,
57:54–61.
Thor K. 2003. Serotonin and norepinephrine involvement in efferent
pathways to the urethral rhabdosphincter: Implication for treating stress
urinary incontinence. Urology, 62(Suppl 4A):3–9.
van Kerrebroeck P, Abrams P, Lange R, et al. 2004. Duloxetine versus
placebo in the treatment of European and Canadian women with stress
urinary incontinence. B J Obstet Gynaecol, 111:249–57.
Wong D, Bymaster F, Mayle D, et al. 1993. LY24868, a new inhibitor of
serotonin and norepinephrine uptake. Neuropsychopharmacology,
8:23–33.